share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  06/11 08:32
Moomoo AI 已提取核心信息
On June 6, 2024, SeaStar Medical Holding Corporation, a Delaware-incorporated company listed on the Nasdaq Stock Market under the symbol ICU, reported significant financial transactions with an institutional investor known as Investor D. The company redeemed $0.7 million of the remaining outstanding convertible notes that were originally issued on December 11, 2023, along with accrued interest and make-whole amounts. The redemption was executed at 200% of the conversion amount as per the terms agreed upon. Concurrently, Investor D converted approximately $0.6 million of unpaid principal and $0.7 million of unpaid interest and make-whole amounts into 2,321,429 shares of common stock, which, due to a 25-for-1 reverse stock split effective from June 7, 2024, equates to 92,858 post-split shares. Following these transactions, there are no remaining outstanding Investor D convertible notes. However, Investor D retains warrants to purchase around 3,158,086 shares of SeaStar Medical's stock at a weighted-average exercise price of $0.55, which adjusts to $13.75 post-reverse split. The company's CEO, Eric Schlorff, signed off on the report.
On June 6, 2024, SeaStar Medical Holding Corporation, a Delaware-incorporated company listed on the Nasdaq Stock Market under the symbol ICU, reported significant financial transactions with an institutional investor known as Investor D. The company redeemed $0.7 million of the remaining outstanding convertible notes that were originally issued on December 11, 2023, along with accrued interest and make-whole amounts. The redemption was executed at 200% of the conversion amount as per the terms agreed upon. Concurrently, Investor D converted approximately $0.6 million of unpaid principal and $0.7 million of unpaid interest and make-whole amounts into 2,321,429 shares of common stock, which, due to a 25-for-1 reverse stock split effective from June 7, 2024, equates to 92,858 post-split shares. Following these transactions, there are no remaining outstanding Investor D convertible notes. However, Investor D retains warrants to purchase around 3,158,086 shares of SeaStar Medical's stock at a weighted-average exercise price of $0.55, which adjusts to $13.75 post-reverse split. The company's CEO, Eric Schlorff, signed off on the report.
2024年6月6日，纳斯达克上市的海星医疗控股公司（注册地为特拉华州）以标的代码ICU进行交易，向一位机构投资人（简称D投资人）报告了重大财务交易。该公司已按约定条款赎回了于2023年12月11日发行的剩余未转换可转换公司债券的价值为70万美元的部分、计息及补偿金额。该赎回价格为转换金额的200%。同时，D投资人按照约定将未付本金约60万美元以及未付的利息和补偿金额约70万美元，转换为2321429股普通股。由于自2024年6月7日生效的1股股票拆分后相当于25股，因此该转换相当于92858股股票。完成这些交易后，D投资人不再持有任何未转换的可转换公司债券。然而，D投资人保留了以约0.55美元的加权平均行权价购买约3158086股海星医疗公司股票的认股权。在股票拆分后，该价格调整为13.75美元。该公司的首席执行官埃里克·斯克罗夫（Eric Schlorff）已签署了该报告。
2024年6月6日，纳斯达克上市的海星医疗控股公司（注册地为特拉华州）以标的代码ICU进行交易，向一位机构投资人（简称D投资人）报告了重大财务交易。该公司已按约定条款赎回了于2023年12月11日发行的剩余未转换可转换公司债券的价值为70万美元的部分、计息及补偿金额。该赎回价格为转换金额的200%。同时，D投资人按照约定将未付本金约60万美元以及未付的利息和补偿金额约70万美元，转换为2321429股普通股。由于自2024年6月7日生效的1股股票拆分后相当于25股，因此该转换相当于92858股股票。完成这些交易后，D投资人不再持有任何未转换的可转换公司债券。然而，D投资人保留了以约0.55美元的加权平均行权价购买约3158086股海星医疗公司股票的认股权。在股票拆分后，该价格调整为13.75美元。该公司的首席执行官埃里克·斯克罗夫（Eric Schlorff）已签署了该报告。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息